Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT mutations and high tumour mutational burden.

Joanne D StocktonLouise TeeCelina WhalleyJonathan JamesMark DilworthRachel WheatThomas Nietonull nullIan GehJoão D Barros-SilvaAndrew D Beggs

Published in: Radiation oncology (London, England) (2021)

The phenomenon of pathCR in rectal cancer may be related to immunovisibility caused by a high tumour mutational burden phenotype. Potential therapy resistance mechanisms involve the PI3K/AKT/mTOR signalling pathway, but tumour heterogeneity does not seem to play a role in resistance.

Keyphrases

rectal cancer
locally advanced
signaling pathway
risk factors
radiation therapy
stem cells
climate change
wild type
replacement therapy